A comparison of glycaemic effects of sitagliptin and sulfonylureas in elderly patients with type 2 diabetes mellitus (Q41477500)

1 October 2017

A comparison of glycaemic effects of sitagliptin and sulfonylureas in elderly patients with type 2 diabetes mellitus (English)

1 reference

1 October 2017

1 reference

R R Shankar

1

1 reference

1 October 2017

L Xu

2

1 reference

1 October 2017

G T Golm

3

1 reference

1 October 2017

E A O'Neill

4

1 reference

1 October 2017

B J Goldstein

5

1 reference

1 October 2017

K D Kaufman

6

1 reference

1 October 2017

S S Engel

7

1 reference

1 October 2017

4 February 2015

1 reference

International Journal of Clinical Practice

1 October 2017

1 reference

1 October 2017

69

1 reference

1 October 2017

6

1 reference

1 October 2017

626-631

1 reference

Trends in death rates among U.S. adults with and without diabetes between 1997 and 2006: findings from the National Health Interview Survey

1 October 2017

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12607

Global prevalence of diabetes: estimates for the year 2000 and projections for 2030

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12607

Severe sulfonylurea-induced hypoglycemia: a problem of uncritical prescription and deficiencies of diabetes care in geriatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12607

Hypoglycemia unawareness in older compared with middle-aged patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12607

Oral antidiabetic treatment in type-2 diabetes in the elderly: balancing the need for glucose control and the risk of hypoglycemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12607

Risk of Hypoglycaemia with Oral Antidiabetic Agents in Patients with Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12607

Hypoglycaemia in patients with type 2 diabetes treated with a combination of metformin and sulphonylurea therapy in France

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12607

Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: focus on sitagliptin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12607

Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12607

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12607

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12607

The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12607

Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12607

Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12607

Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12607

Efficacy and safety of initial combination treatment with sitagliptin and pioglitazone--a factorial study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12607

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12607

Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12607

Comparative analysis of two rates

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12607

Sulfonylurea receptors and mechanism of sulfonylurea action

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12607

Complementing insulin therapy to achieve glycemic control

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12607

Hypoglycemia-associated autonomic failure in advanced type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12607

21 January 2018

Identifiers

DOI

10.1111/IJCP.12607

1 reference

1 October 2017

1 reference